AdAlta Limited (ASX:1ADO)

Market Cap	2.89M -81.4%
Revenue (ttm)	677.01K -61.0%
Net Income	-4.50M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	650,000
Average Volume	2,399,247
Open	0.0020
Previous Close	n/a
Day's Range	0.0020 - 0.0020
52-Week Range	0.0010 - 0.0040
Beta	n/a
RSI	48.15
Earnings Date	Nov 19, 2025

About AdAlta

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe Univers...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 1
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: 1ADO